Merger war explodes: Pfizer drags Metsera and Novo Nordisk to court over ‘illegal’ bid

Pfizer Inc. (NYSE: PFE) has launched a legal offensive against Metsera Inc. (NASDAQ: MTSR), its board of directors, and Novo Nordisk A/S (NYSE: NVO), alleging a breach of contract and fiduciary obligations in a heated acquisition dispute. The lawsuit, filed in the Delaware Court of Chancery, seeks to block a competing proposal from Novo Nordisk that Pfizer claims was structured to unlawfully disrupt its pending merger with Metsera.

This unfolding drama pits three major pharmaceutical entities against one another in a contest for control of a promising obesity drug pipeline, potentially worth billions. Pfizer asserts that it had already cleared all antitrust and regulatory hurdles for its merger with Metsera and was poised to close the transaction following a shareholder vote scheduled for November 13, 2025. However, Novo Nordisk made a rival offer which Pfizer alleges is not only less likely to be completed but also carries substantial legal and regulatory risks, making it non-compliant with the agreed merger terms.

According to the complaint, Pfizer has requested a temporary restraining order to prevent Metsera from terminating the merger agreement. It accuses both Metsera and Novo Nordisk of breaching legal duties and engaging in tortious interference. Pfizer is also seeking injunctive relief and monetary damages to enforce the terms of the original agreement.

Why did Pfizer initiate legal action against Metsera and Novo Nordisk?

Pfizer claims the original merger agreement with Metsera included strict provisions governing competing bids and fiduciary duties. It argues that Metsera’s directors violated these conditions by entertaining a rival proposal from Novo Nordisk that closely resembles an earlier rejected offer. That previous bid, which had the same structure as the current one, was previously deemed by Metsera’s own board to pose significant antitrust risks. Pfizer asserts that nothing material has changed since that determination, yet the board has now reversed its position in a manner that undermines the binding agreement already in place.

The American pharmaceutical major contends that Novo Nordisk is attempting to circumvent U.S. regulatory scrutiny by deliberately structuring its proposal to avoid triggering standard antitrust review mechanisms. Pfizer states that this unprecedented structure represents an illegal effort by a market-dominant company to stifle competition in the growing obesity drug market. Adding to the controversy, Pfizer claims that the Novo Nordisk proposal includes a special dividend that would violate Delaware corporate law.

Moreover, Pfizer alleges that Metsera’s directors secured a self-serving indemnification clause from Novo Nordisk, which would shield them from liability for breaching their fiduciary duties. This element of the deal has raised serious governance questions and added fuel to Pfizer’s legal response.

What were the competing offers and how did regulatory timing shape the dispute?

Pfizer’s agreement to acquire Metsera had already received clearance from the United States Federal Trade Commission, which granted early termination under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. With all regulatory approvals in place, Pfizer expected to move forward immediately after the upcoming shareholder vote.

In contrast, Novo Nordisk’s unsolicited bid, estimated to be worth as much as USD 8.5 billion when including milestone payments, is still subject to considerable antitrust risk. Pfizer’s argument is that the new proposal is unlikely to withstand scrutiny due to Novo Nordisk’s dominant position in the obesity treatment space, where it markets the blockbuster drug Wegovy. The Novo Nordisk structure reportedly attempts to avoid antitrust delays through a novel transaction format that Pfizer has framed as a regulatory loophole. Pfizer contends this structure not only makes the deal riskier but disqualifies it from being treated as a “Superior Company Proposal” under its existing merger terms with Metsera.

Pfizer’s legal complaint notes that Metsera had previously rejected a similar offer from Novo Nordisk on regulatory grounds, raising doubts over the board’s sudden change in position. With Pfizer’s deal already cleared, the timing of this reversal has emerged as a central point of contention in the lawsuit.

How are Pfizer, Novo Nordisk, and Metsera stocks reacting to the merger lawsuit and what signals are institutional investors tracking now?

Investor sentiment is cautiously neutral as both Pfizer and Novo Nordisk stocks tread water amid legal uncertainty. Pfizer Inc. shares, trading around USD 24.65, remain near the lower end of their 52-week range. The pharmaceutical firm has faced recent headwinds related to declining COVID-related revenues, but its push into obesity therapeutics is seen as a potential growth avenue. Novo Nordisk A/S, whose shares traded near USD 49.45 on the same day, has seen strong investor interest given its success with semaglutide, but is now facing questions over whether it can legally and strategically execute its proposed acquisition of Metsera.

Institutional investors are now watching closely to see whether the Delaware Chancery Court will grant Pfizer’s request for a restraining order. If Pfizer is successful, Metsera may be forced to honor its original merger agreement, preserving Pfizer’s path into the competitive obesity drug market. If the court rules in favor of Novo Nordisk and Metsera, it could set a new precedent for how large pharmaceutical deals are structured to bypass regulatory review.

Analysts suggest that Pfizer’s aggressive legal strategy is not only an attempt to preserve the current merger but also an effort to signal to the market that it will not tolerate competitive end-runs in highly regulated M&A transactions. The company appears keen on defending both its legal rights and its commercial interests in the increasingly valuable weight-loss drug sector, which could reach USD 150 billion globally in the coming decade.

What are the broader implications for pharmaceutical M&A and regulatory scrutiny?

The outcome of this case could reshape how pharmaceutical companies approach merger agreements, particularly in therapeutic categories like obesity where the stakes are enormous and the number of leading players is limited. Pfizer’s framing of the Novo Nordisk proposal as an antitrust evasion tactic brings wider attention to how regulatory frameworks are adapting or failing to adapt to new corporate strategies in M&A execution.

If courts accept Pfizer’s interpretation, future buyers may be more cautious when offering novel deal structures that lack regulatory transparency. Conversely, a ruling in favor of Novo Nordisk could embolden other acquirers to test the limits of antitrust thresholds through creative structuring.

For Metsera, the controversy highlights the complex decision-making pressures faced by emerging biotech companies that are courted by multiple suitors. The company’s board must now weigh legal exposure, shareholder fiduciary duties, and long-term strategic value under the glare of both regulators and investors.

What’s next and how might this affect the obesity drug race?

All eyes are now on the November 13 shareholder meeting and the court’s response to Pfizer’s motion. Should Pfizer prevail, it will secure access to Metsera’s pipeline, which reportedly includes multiple assets with peak sales potential of more than USD 5 billion. This would significantly bolster Pfizer’s competitive position in a market currently led by Novo Nordisk and Eli Lilly and Company.

If Novo Nordisk emerges victorious, it will strengthen its already formidable position in obesity drugs, though it may still face challenges navigating the regulatory and legal landscape. A protracted legal battle could delay Metsera’s development timelines and affect investor appetite for other emerging biotech firms in similar deal scenarios.

Regardless of the outcome, this high-profile clash between Pfizer, Metsera, and Novo Nordisk has become a case study in how strategic litigation, regulatory interpretation, and M&A competition intersect in the pharmaceutical industry.

What are the key takeaways investors and readers should know about Pfizer’s lawsuit, Metsera’s board actions, and Novo Nordisk’s rival bid?

• Pfizer Inc. has filed suit in the Delaware Court of Chancery alleging breach of contract, breach of fiduciary duty and tortious interference after Metsera, Inc. engaged with a rival proposal from Novo Nordisk A/S.
• Pfizer says its acquisition of Metsera cleared U.S. regulatory review, including early termination of the FTC waiting period under the Hart‑Scott‑Rodino Act, and is ready to close after the scheduled November 13 shareholder vote.
• Pfizer contends that Novo Nordisk’s offer is structured in a way that is unlikely to be completed because of heightened antitrust risk and therefore does not qualify as a “Superior Company Proposal” under the merger agreement.
• The complaint asserts that the Novo Nordisk proposal includes a special dividend and indemnification terms that Pfizer says violate Delaware law and could shield Metsera directors from fiduciary liability.
• A temporary restraining order is sought to stop Metsera from terminating the Pfizer merger agreement while the court considers the case, making the court’s near‑term rulings the primary catalyst for deal direction.
• Market and institutional sentiment is cautious; investors are watching the court’s decision and the Metsera shareholder vote as determinants of which bidder will control Metsera’s obesity drug pipeline and the broader competitive dynamics in the obesity therapeutics market.